What’s new in MS: teratogenicity of disease-modifying drugs, extended interval natalizumab dosing, a potential biomarker, the “MS hug,” and virtual reality therapy.
from Front page feed http://bit.ly/2XiqWxw
from Front page feed http://bit.ly/2XiqWxw
Comments
Post a Comment